– Poised for LifeFlow Expansion in Hospitals and EMS Throughout U.S. –
DURHAM, N.C., May 25, 2023 — 410 Medical, Inc., a medical device company developing innovative technologies for emergency and critical care, announced today it has completed its $7.5 million Series B financing. This round of funding, with an initial closing late in 2022, was led by Hatteras Venture Partners, with participation from new and existing investors including Orlando Health Ventures, Ballad Ventures, Catalyst by Wellstar, OSF Healthcare, and WakeMed.
“Many years ago I was struck by our inability to provide timely resuscitation for patients with shock,” said Mark Piehl, MD, co-founder and chief medical officer at 410 Medical. “Now 10 years since the creation of 410 Medical, emergency and critical care clinicians have used LifeFlow to improve care for over 20,000 patients. We are thankful for the many EMS, hospital, and military partnerships we have developed and for the investors who have made this journey possible and helped us to affect patient care in the way that we have.”
410 Medical’s lead product, LifeFlow®, is designed to help clinicians more effectively and efficiently deliver blood and IV fluids to critically ill patients. Severe sepsis affects over 1 million adults and children each year in the U.S., and it is the most frequent cause of death in hospitalized patients. Trauma is the leading cause of death in patients less than 45 years old. In these and other conditions leading to hypotension and shock, rapid delivery of blood or IV fluid is a life-saving therapy, yet with traditional infusion methods, providers often fail to achieve timely resuscitation or adhere to published guidelines. Since FDA clearance in 2016, LifeFlow has been adopted at many leading healthcare systems in the U.S., including Orlando Health, Ballad Health and Wellstar.
“We are enthusiastic about this partnership’s transformative impact on our communities, as we continue our unwavering pursuit of providing exceptional care to those we serve,” said Amit Vashist, MD, chief clinical officer for Ballad Health and clinical advisor for Ballad Ventures. “Incorporating this leading-edge medical device into our pediatric and emergency settings has already made a significant impact in our ability to deliver timely and effective resuscitation to patients in need, elevating their chances of survival and promoting their overall well-being.”
About 410 Medical, Inc.
Founded in 2013, 410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. 410 Medical’s first product, LifeFlow, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening illnesses such as sepsis and shock. LifeFlow was cleared by the FDA for human use in 2016. For more information, visit www.410medical.com.
About Ballad Ventures
Ballad Ventures is a venture capital platform focused on investing in innovative ideas that transform healthcare experience, cost, access and outcomes for the better. As the venture capital arm of Ballad Health – an integrated community health improvement organization serving 29 counties of the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, Northwest North Carolina and Southeast Kentucky – we seek opportunities that drive the mission, vision and strategic initiatives of the organization, such as leading in the adoption of value-based payments, addressing health-related social needs, funding clinical and health systems research and committing to long-term investments in strong children and families. To learn more, visit www.balladventures.com.
About Catalyst by Wellstar
Catalyst by Wellstar is the first-of-its-kind innovation company and venture firm created and operated within a health ecosystem to holistically address healthcare disruption by harnessing problems, building solutions, deploying capital, and establishing strategic partnerships across industries. Catalyst is actively investing in Pre-seed to Series A startups that align with the company’s six focus areas: customer experience, data, digital health, future of work, supply chain and logistics, and sustainability. Visit Catalyst.wellstar.org to learn more.
Media Contact:
Carla Hoffman
choffman@410medical.com